Dan Vogl, MD | Authors

November 25, 2022

Closing out their module on transplant-ineligible NDMM management, expert panelists consider best practices regarding duration of therapy and adjustments to drug regimens.

November 25, 2022

Comprehensive discussion on the array of treatment regimens available for patients with transplant-ineligible NDMM and how best to sequence therapy.

November 18, 2022

Expert oncologists focus on a final patient case of transplant-ineligible newly diagnosed multiple myeloma and reflect on the treatment armamentarium in this setting.

November 18, 2022

Before closing out their review of treatment for transplant-eligible multiple myeloma, panelists consider how they might adjust therapy to optimize tolerability or efficacy.

November 11, 2022

Shared insight on the optimal selection of induction therapy for patients with high-risk transplant-eligible newly diagnosed multiple myeloma.

November 11, 2022

Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists define high-risk disease and how it impacts treatment.

November 04, 2022

A brief discussion on the use of consolidation therapy to improve patient outcomes following transplant in newly diagnosed multiple myeloma.

November 04, 2022

Expert perspectives on the real-world use of induction therapy and transplant in patients with transplant-eligible newly diagnosed multiple myeloma.

October 28, 2022

Comprehensive insight on induction therapy regimens in transplant-eligible newly diagnosed multiple myeloma based on the GRIFFIN, MASTER, and DETERMINATION clinical studies.

October 28, 2022

Expert panelists review the case of transplant-eligible newly diagnosed multiple myeloma and consider optimal selection of induction therapy.